1000576-51-1 Usage
General Description
3-cyano-1H-Indole-6-carboxylic acid methyl ester is a chemical compound with the molecular formula C13H10N2O2. It is a methyl ester derivative of 3-cyano-1H-indole-6-carboxylic acid, and it is commonly used in organic synthesis and pharmaceutical research. 3-cyano-1H-Indole-6-carboxylic acid methyl ester has potential biological activities and is of interest for its potential use as a building block in drug development. It is also used as a reagent in chemical reactions and as a precursor for the synthesis of various biologically active molecules. Its structure and properties make it a versatile compound for research and industrial applications.
Check Digit Verification of cas no
The CAS Registry Mumber 1000576-51-1 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,0,0,0,5,7 and 6 respectively; the second part has 2 digits, 5 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 1000576-51:
(9*1)+(8*0)+(7*0)+(6*0)+(5*5)+(4*7)+(3*6)+(2*5)+(1*1)=91
91 % 10 = 1
So 1000576-51-1 is a valid CAS Registry Number.
1000576-51-1Relevant articles and documents
Discovery of N-(4′-(indol-2-yl)phenyl)sulfonamides as novel inhibitors of HCV replication
Chen, Guangming,Ren, Hongyu,Turpoff, Anthony,Arefolov, Alexander,Wilde, Richard,Takasugi, James,Khan, Atiyya,Almstead, Neil,Gu, Zhengxian,Komatsu, Takashi,Freund, Connie,Breslin, Jamie,Colacino, Joseph,Hedrick, Jean,Weetall, Marla,Karp, Gary M.
, p. 3942 - 3946 (2013/07/27)
A series of novel 2-phenylindole analogs were synthesized and evaluated for activity in subgenomic HCV replicon inhibition assays. Several compounds containing small alkyl sulfonamides on the phenyl ring exhibiting submicromolar EC50 values against the genotype 1b replicon were identified. Among these, compound 25d potently inhibited the 1b replicon (EC50 = 0.17 μM) with 147-fold selectivity with respect to cytotoxicity. Compound 25d was stable in the presence of human liver microsomes and had a good pharmacokinetic profile in rats with an IV half-life of 4.3 h and oral bioavailability (F) of 58%.
